{"id":"W7116872897","doi":"10.1016/j.annonc.2025.10.100","title":"273MO Safety results in Asian participants (pts) from the phase IIIb SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for pts with unresectable hepatocellular carcinoma (uHCC) and a poor prognosis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Durvalumab; Tremelimumab; Hepatocellular carcinoma; Phases of clinical research; Carcinoma; Hepatocellular cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001034059,0.0003084539,0.0005533722,0.000149578,0.000265807,0.0005619732,0.0002151485,0.0003176272,0.003668805],"category_scores_gemma":[0.0008604008,0.0001771244,0.0007639323,0.0002731482,0.0001530111,0.0002874641,0.0002453239,0.000728235,0.0007359192],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000309425,"about_ca_system_score_gemma":0.000475371,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008331882,"about_ca_topic_score_gemma":0.001771475,"domain_scores_codex":[0.9996673,0.0001442968,0.00002127164,0.00005616434,0.00005605517,0.00005504431],"domain_scores_gemma":[0.9995444,0.0000859232,0.0001565196,0.00004590952,0.00006393155,0.0001031934],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4815308,0.004236208,0.3176455,0.001001018,0.005454128,0.0005102344,0.0004083646,0.001072023,0.03918749,0.0004256488,0.01052724,0.1380013],"study_design_scores_gemma":[0.1123519,0.09799131,0.7413085,0.0001921471,0.00815564,0.00133894,0.0003882755,0.002271861,0.009337317,0.0005759224,0.02600965,0.00007845585],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992603,0.00123417,0.0002237906,0.0002352249,0.00005271804,0.000143639,0.002596722,0.00003633307,0.002874463],"genre_scores_gemma":[0.9939181,0.0005767547,0.000221722,0.0003689486,0.00006467071,0.0001798396,0.002955736,0.00001528916,0.001698801],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003668805,"threshold_uncertainty_score":0.01227343,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1659568706614315,"score_gpt":0.3774655174604004,"score_spread":0.2115086467989689,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}